1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow ANX005: new trials by email Literature Review of ANX005 trials Research Report on ANX005
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS) ANX005, Intravenous immunoglobulin - Guillain-Barré Syndrome | Phase 1 | Completed | Annexon, Inc. | 14 | 2020-01-29 | 2021-08-11 |
| Single Dose Study of ANX005 in Healthy Volunteers ANX005, IVIg, Placebos - Safety and Tolerability in Healthy Volunteers | Phase 1 | Terminated | Annexon, Inc. | 27 | 2016-12-01 | 2020-08-20 |
Annexon, Inc. (2)
Australia (1) · Bangladesh (1) · Denmark (1)
Jason Lickliter, MBBS PhD (1) · Sandy Calman, MD (1)